Business Context and Reporting Period
This Form 10-Q covers the quarter ended March 31, 2004, for Wilson Greatbatch Technologies, Inc. (Note: The input metadata referenced "Integer Holdings Corp," but the filing text explicitly identifies the registrant as Wilson Greatbatch Technologies, Inc.). The company operates two segments: Implantable Medical Components (IMC), producing batteries and components for cardiac devices, and Electrochem Power Solutions (EPS), producing high-performance batteries for commercial applications. During the quarter, the company completed the acquisition of NanoGram Devices Corporation (NDC) to expand its battery product line.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Sales | $55,525,000 | $54,857,000 |
| Gross Profit | $23,175,000 | $22,813,000 |
| Operating Income | $10,373,000 | $9,677,000 |
| Net Income | $6,619,000 | $6,037,000 |
| Diluted EPS | $0.31 | $0.28 |
| Operating Margin | 18.7% | 17.6% |
| Net Margin | 11.9% | 11.0% |
| Cash and Equivalents (End of Period) | $74,253,000 | $2,203,000 |
| Working Capital | $131,187,000 | N/A |
| Long-Term Debt (Convertible Notes) | $170,000,000 | $170,000,000 |
Cash Flow: Net cash provided by operating activities was $2,575,000. Net cash used in investing activities was $48,209,000, primarily due to the $45.4 million acquisition of NDC and $6.6 million in capital expenditures.
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 1% to $55.5 million. The IMC segment grew 1% driven by a 23% increase in feedthroughs and 18% increase in ICD capacitors, offset by declines in ICD batteries (-12%) and enclosures (-22%). The EPS segment grew 6% due to higher demand in oceanographic applications.
- Profitability: Operating income rose 7% to $10.4 million, and operating margin improved to 18.7% from 17.6%, attributed to cost controls and SG&A reductions.
- Acquisition Impact: The acquisition of NDC added $34.9 million in goodwill and $16.5 million in intangible assets. Research and development expenses increased 7% due to the inclusion of NDC's development costs.
- Liquidity: Cash and cash equivalents decreased by $45.2 million to $74.3 million, primarily driven by the cash payment for the NDC acquisition.
Guidance, Outlook, and Risks
Outlook and Commentary: Management highlighted the successful implementation of the Oracle ERP system for the EPS unit and the signing of development agreements for new capacitor and high-rate battery technologies with major CRM customers. The company expects Research and Development expenses to increase by an estimated $6.0 million to $7.0 million for the remainder of 2004 as NDC is fully integrated. Capital spending is expected to remain elevated due to the build-out of a new medical battery plant and ERP implementation.
Risks and Contingencies: The company faces risks related to dependence on a limited number of customers, pricing pressure, and the ability to successfully integrate acquisitions. There are no material legal proceedings pending. The company maintains a $20 million unused credit line and considers its liquidity strong despite the recent cash outflow for the acquisition.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost synergies associated with the integration of NanoGram Devices Corporation (NDC).
- Capital Expenditures: Monitor the $7.0 million Q1 capital spending trend, specifically regarding the new medical battery plant and ERP rollout.
- Product Mix Shifts: Assess the sustainability of sales growth in feedthroughs and capacitors versus the decline in core battery and enclosure sales.
- Debt Structure: Review the terms of the $170 million convertible subordinated notes and the impact of rising interest expense on future margins.
- Customer Concentration: Evaluate the risk associated with the four major CRM customers adopting the company's capacitor technology.